肝脏影像报告和数据系统治疗反应算法预测经局部区域治疗肝细胞癌术后复发
本研究纳入2010至2016年间接受局部区域治疗后行肝移植或根治性切除的73例肝细胞癌患者共115个病灶,评估LI-RADS治疗反应(LR-TR)分类及临床因素对无复发生存期和总生存期的预测价值。结果显示,手术时LR-TR存活类别、术前AFP>200 ng/mL、LRT次数>3次及切除(对比肝移植)为复发独立预测因素,风险评分可将患者分为低、中、高风险组,1年RFS率分别为97.0%、78.3%、35.0%(p<0.001)。
要点
- 手术时LR-TR存活类别是术后复发的独立预测因素(HR 3.84)。
- 联合LR-TR分类与临床因素的风险评分可分层1年RFS率35.0%至97.0%。
- 手术时超出米兰标准及术后第一年内复发与总生存期差相关。
核心结论
- 在经LRT治疗的HCC中,以较少LRT次数达到非LR-TR存活病变并经肝移植切除者复发较少。
研究设计与样本
- 回顾性分析连续HCC患者,2010至2016年接受LRT后行肝移植或根治性切除,具备基线及术后至手术前随访CT/MRI,共73例患者115个病灶;采用Cox比例风险模型评估LR-TR分类及其他特征,Kaplan-Meier法和log-rank检验估计并比较RFS。
诊断标准与关键数值
- 手术时LR-TR存活类别预测复发HR 3.84(95%CI 1.04,14.16);术前AFP>200 ng/mL HR 3.63(95%CI 1.63,8.10);LRT次数>3次 HR 4.99(95%CI 1.73,14.38);切除对比肝移植 HR 3.35(95%CI 1.39,8.09);风险评分将患者分为低、中、高风险组,1年RFS率分别为97.0%、78.3%、35.0%(p<0.001)。
临床应用与阅片要点
- 阅片时按LR-TR算法评估手术时是否存在存活病变,并结合术前AFP水平、LRT次数及手术方式(切除或移植)综合判断术后复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: In HCC, locoregional therapy (LRT) is performed as a bridging or downstaging treatment before curative surgery. The impact of the LI-RADS Treatment Response (LR-TR) algorithm on surgical outcomes remains unknown. We aimed to evaluate radiologic and clinical factors predicting recurrence-free survival (RFS) and overall survival (OS) after curative surgery for LRT-treated HCC.
MATERIALS AND METHODS: Consecutive HCC patients who underwent liver transplantation or curative resection after LRT from 2010 to 2016 and had baseline and follow-up post-LRT CT/MRI up to the point of surgery were included. The LR-TR category at the time of surgery and other features were assessed using Cox proportional hazard models. RFS was estimated and compared using the Kaplan-Meier method with log-rank tests.
RESULTS: We evaluated 73 patients with 115 lesions. The LR-TR viable category at the time of surgery (hazard ratio [HR], 3.84; 95% confidence interval [CI]: 1.04, 14.16), preoperative AFP > 200 ng/mL (HR, 3.63; 95% CI: 1.63, 8.10), LRT sessions > 3 (HR, 4.99; 95% CI: 1.73, 14.38), and resection (HR, 3.35; 95% CI: 1.39, 8.09) independently predicted recurrence. The risk score categorized the patients into poor, intermediate, and favorable-risk groups with 1-year RFS rates of 35.0%, 78.3%, and 97.0%, respectively (p < 0.001). Outside Milan at the time of surgery (HR, 5.79; 95% CI: 1.94, 17.07) and recurrence within the first postoperative year (HR, 17.66; 95% CI: 6.42, 48.56) predicted death.
CONCLUSION: In LRT-treated HCC, non-LR-TR viable disease achieved within fewer LRT sessions and removed by liver transplantation recurred less.
KEY POINTS: • The Liver Imaging Reporting and Data System treatment response (LR-TR) viable disease (hazard ratio [HR], 3.84; p = 0.043), preoperative serum AFP level > 200 ng/mL (HR, 3.63; p = 0.002), more than three locoregional treatment (LRT) sessions (HR, 4.99; p = 0.003), and resection compared to liver transplantation (HR, 3.35; p = 0.001) were the independent predictors for postsurgical recurrence in LRT-treated HCCs. • A scoring system combining LR-TR categories and key clinical factors stratifies the patients into poor, intermediate, and favorable recurrence risk groups, with 1-year RFS rates of 35.0%, 78.3%, and 97.0%, respectively (p < 0.001). • Outside Milan at the time of surgery (HR, 5.79; p = 0.001) and recurrence within the first postoperative year (HR, 17.66; p < 0.001) were associated with poor overall survival.
引用
- Youn, Kim, Kim, et al. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy-treated hepatocellular carcinoma. Eur Radiol. 2022. PMID: 35348864. doi:10.1007/s00330-022-08720-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。